BCL-2 — Drug Target

All drugs that target BCL-2 — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

BCL-2 inhibitor · BCL-2 inhibitor, Chemotherapy · Bcl-2 inhibitor · BCL-2 inhibitor/hypomethylating agent

Marketed (3)

• Venetoclax (VEN) · Nanfang Hospital, Southern Medical University · BCL-2 inhibitor · Oncology
  Venetoclax is a selective BCL-2 inhibitor that promotes apoptosis by blocking the anti-apoptotic protein BCL-2 in cancer cells.
• Rd · Ascentage Pharma Group Inc. · BCL-2 inhibitor · Oncology
  Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.
• VEN · Janssen Research & Development, LLC · BCL-2 inhibitor · Oncology
  Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2 that promotes cancer cell death by restoring apoptosis.

Phase 3 pipeline (7)

• SCT400 plus CHOP · Sinocelltech Ltd. · BCL-2 inhibitor, Chemotherapy · Oncology
  SCT400 is a small molecule inhibitor of the BCL-2 family, while CHOP is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone.
• ARM A: Active Comparator Drug · Grupo Argentino de Tratamiento de la Leucemia Aguda · BCL-2 inhibitor · Oncology
  This drug works by inhibiting the BCL-2 protein, preventing cancer cell survival.
• Placebo for Navitoclax · AbbVie · Oncology
  Navitoclax is an inhibitor of BCL-2 family proteins.
• BGB-A445 · BeiGene · Bcl-2 inhibitor · Oncology
  BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.
• Venetoclax 400 · Stichting Hemato-Oncologie voor Volwassenen Nederland · BCL-2 inhibitor · Oncology
  Venetoclax is a small molecule inhibitor of the BCL-2 protein, which is involved in apoptosis regulation.
• Venetoclax-Decitabine/Azacitidine Association · The First Affiliated Hospital with Nanjing Medical University · BCL-2 inhibitor/hypomethylating agent · Oncology
  Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine work as hypomethylating agents to restore normal gene expression.
• Venetoclax-Decitabine/Azacitidine-Aclarubicin Association · The First Affiliated Hospital with Nanjing Medical University · BCL-2 inhibitor · Oncology
  Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine-Aclarubicin combination works by inducing DNA hypomethylation and promoting apoptosis in cancer cells.

Phase 2 pipeline (3)

• ABL-101 · NHS Greater Glasgow and Clyde · BCL-2 inhibitor · Oncology
  ABL-101 is a small molecule inhibitor of the BCL-2 family.
• Induction Venetoclax · PrECOG, LLC. · BCL-2 inhibitor · Oncology
  BCL-2 inhibitor
• APG-115 · Ascentage Pharma Group Inc. · BCL-2 inhibitor · Oncology
  APG-115 is a small molecule inhibitor of BCL-2 family proteins.